Improving cancer immunotherapy using engineered nanoparticles
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
['FUNDING_R01'] · VANDERBILT UNIVERSITY · NIH-11079451
This study is looking at a new way to make cancer treatments work better by using tiny particles that help boost your immune system to fight tumors, so more people with cancer can benefit from these therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY (nih funded) |
| Locations | 1 site (Nashville, UNITED STATES) |
| Trial ID | NIH-11079451 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of cancer immunotherapy by developing nanoparticles that activate the STING pathway, which plays a crucial role in the immune response against tumors. The approach involves creating specialized nanoparticles that can deliver immune-boosting agents directly to cancer cells, thereby increasing the number and function of immune cells that can attack the tumor. By improving the delivery and potency of these agents, the research aims to make immunotherapy more effective for a larger group of cancer patients. This could potentially allow patients with advanced cancer to benefit from treatments that are currently limited to localized administration.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancer who have not responded to traditional immunotherapy treatments.
Not a fit: Patients with early-stage cancer or those who are not candidates for immunotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of immunotherapy for cancer patients, leading to better treatment outcomes.
How similar studies have performed: Other research has shown promising results using similar nanoparticle approaches to enhance cancer immunotherapy, indicating a potential for success in this area.
Where this research is happening
Nashville, UNITED STATES
- VANDERBILT UNIVERSITY — Nashville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WILSON, JOHN TANNER — VANDERBILT UNIVERSITY
- Study coordinator: WILSON, JOHN TANNER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy